

28 **Abstract**

29

30 Musculoskeletal conditions, including fractures, can have severe and long-lasting
31 consequences. Higher body mass index in adulthood is widely acknowledged to be
32 protective for most fracture sites, indicated through previous clinical and epidemiological
33 observational research. However, the association between weight and bone health is
34 complex and sources of bias, induced by confounding factors, may have distorted
35 earlier findings. Employing a lifecourse Mendelian randomization (MR) approach by
36 using genetic instruments to separate effects at different life stages, this investigation
37 aims to explore how prepubertal and adult body size independently influence fracture
38 risk in later life.

39

40 Using data from a large UK-based prospective cohort, univariable and multivariable MR
41 with inverse variance weighted meta-analysis were conducted to simultaneously
42 estimate the effects of age-specific genetic proxies for body size (n=453,169) on the
43 odds of fracture in later life (n=416,795). A two-step MR framework was additionally
44 applied to elucidate potential mediators. Univariable and multivariable MR indicated
45 strong evidence that higher body size in childhood reduced fracture risk in later life (OR,
46 95% CI: 0.89, 0.82 to 0.96, P=0.005 and OR, 95% CI: 0.76, 0.69 to 0.85, P=1x10⁻⁶,
47 respectively). Conversely, higher body size in adulthood increased fracture risk (OR,
48 95% CI: 1.08, 1.01 to 1.16, P=0.023 and OR, 95% CI: 1.26, 1.14 to 1.38, P=2x10⁻⁶,
49 respectively). Two-step MR analyses suggested that the effect of higher body size in
50 childhood on reduced fracture risk was mediated by its influence on higher estimated
51 bone mineral density (eBMD) in adulthood.

52

53 This investigation provides novel evidence that higher body size in childhood has a
54 direct effect on reduced fracture risk in later life through its influence on increased
55 eBMD. Results indicate that higher body size in adulthood is a risk factor for fractures,
56 opposing findings from earlier research. Protective effect estimates previously observed
57 are likely attributed to childhood effects.

58 Introduction

59

60 Musculoskeletal conditions are a leading cause of disability worldwide, affecting nearly
61 2 billion people (1). Associated injuries, including fractures and falls, can lead to serious
62 and long-lasting effects, particularly in later life (2). With hip fracture predicted to incur
63 an annual worldwide cost of US\$132 billion by 2050 (3), not only the social, but
64 economic burden of these health states make prevention of such conditions an
65 important public health goal (4).

66

67 Considerable changes occur in body composition over the lifecourse (5). Bone mass is
68 accrued until peak bone mass is reached in the third decade of life (6). It then remains
69 stable until menopause in women, and later life in men, where sex steroid deficiency
70 begins to drive cortical bone loss (7, 8). Lean mass additionally increases during growth
71 in childhood, remaining largely stable following puberty until falling later in life (9).
72 Conversely, body fat tends to rise in older age groups, with obesity prevalence peaking
73 in individuals aged 60 to 69 years in high-income countries (10, 11). Several meta-
74 analyses have pointed to a complex association between body mass index (BMI) and
75 fracture risk (12-14). Although higher BMI in adulthood is widely acknowledged to be a
76 protective factor for most sites of fragility fracture (12, 13), studies have shown
77 conflicting results with some evidence suggesting that obesity may be related to an
78 increased risk of fracture (14, 15). Mendelian randomization (MR) investigations exploit
79 the quasi-random assortment of genetic variants independent of other traits to mitigate
80 against false inferences resulting from confounding and reverse causality (16-18). Using
81 the principles of MR, investigations have indicated that higher adiposity increases bone
82 mineral density (BMD) in childhood (16) and that low BMD increases the risk of fracture
83 (19). Moreover, a population-based birth cohort study supported by a subsequent MR
84 investigation identified fat mass as a positive determinant of bone mass and size in
85 prepubertal children (20, 21), pointing to the positive effects of loading on bone
86 formation at a young age (16). Fat mass may stimulate bone growth in childhood
87 through a direct mechanical action of increased load (22), or indirectly by association
88 with increased lean mass, since both are strongly correlated across the whole range of

89 body mass (23). It is therefore plausible that the protective effect estimates observed
90 between BMI in adults and fracture risk in later life, could be attributed to the effects of
91 higher body size that may have exerted an influence on the skeleton in childhood.

92

93 Separating the effects of body size at different stages of the lifecourse is challenging,
94 particularly due to the influence of confounding factors, often afflicting observational
95 studies. This is a key motivation behind using a lifecourse MR approach, which intends
96 to estimate the causal effect of time-varying modifiable risk factors under specific
97 assumptions; the instrumental variables used must i) associate with the exposure of
98 interest conditional on the other exposures (the ‘relevance’ assumption), ii) not affect
99 the outcome except through the exposures (the ‘exclusion restriction’ assumption) and
100 iii) be independent of all confounders, both observed and unobserved, of any of the
101 exposures and outcome (the ‘exchangeability’ assumption) (24). The aim of this
102 investigation was to apply this approach to explore how body size at different stages in
103 the lifecourse modifies the risk of fractures in later life. First, we conducted univariable
104 MR to estimate the ‘total’ effect of early life body size on the odds of fracture (**Figure**
105 **1A**). Multivariable MR, an extension of MR that employs multiple genetic variants
106 associated with multiple measured risk factors to simultaneously estimate the causal
107 effect of each exposure on the outcome of interest, was then employed (25). This was
108 to estimate the ‘direct’ and ‘indirect’ effects of childhood body size on the odds of
109 fracture in later life, by taking adulthood body size into account (**Figure 1B**). We then
110 applied the principles of MR in a two-step framework (26) to assess potential mediators;
111 by examining calcium and vitamin D levels, as well as BMD in adulthood, estimated by
112 quantitative ultrasound of the heel calcaneus (hereafter, “eBMD”) (**Figure 1C**). Given
113 the literature, suggesting that effects of weight are often sex-specific (27), we explored
114 these questions separately by sex. We examined three hormones (bioavailable
115 testosterone, total testosterone, and sex hormone binding globulin (SHBG)) shown to
116 be related to BMI and bone health, as potential mediators between childhood BMI and
117 both fracture risk in later life and eBMD, in the sex-stratified population (28-31).

118

119

120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142




Figure 1. Directed acyclic graphs indicating three scenarios to explain the causal effect between childhood body size and fracture risk in later life.

(A) Univariable Mendelian randomization measuring the total effect of body size in childhood on the odds of fracture in later life. (B) Multivariable Mendelian randomization measuring the direct and indirect effect of body size in childhood and adulthood on the odds of fracture in later life. (C) Two-step Mendelian randomization measuring the total effect of body size in childhood on the mediator (Step 1) and the total effect of the mediator on the odds of fracture in later life (Step 2), allowing the measurement of the

151 indirect effect of body size in childhood on the odds of fracture in later life via the
152 mediator, e.g., estimated bone mineral density.

153

154 **Materials and methods**

155

156 Data resources

157

158 Genetic variants strongly associated with childhood and adult body size (using $P <$
159 5×10^{-8} and $r^2 < 0.001$) were identified in a large-scale genome-wide association study
160 (GWAS), previously undertaken in the UK Biobank study on 453,169 individuals,
161 adjusting for age, sex, and genotyping chip (32, 33). UK Biobank data were collected
162 between 2006 and 2010 on individuals aged between 40 and 69 years old at baseline,
163 from clinical examinations, assays of biological samples, detailed information on self-
164 reported health characteristics, and genome-wide genotyping, using a prospective
165 cohort study design (33). The childhood body size measure applied in this study, utilised
166 recall questionnaire data, involving responses from adult participants who were asked
167 whether, compared to the average, they were ‘thinner’, ‘about average’ or ‘plumper’,
168 when they were aged 10 years old. The adult body size variable was derived using
169 clinically measured body mass index (BMI) data (mean age 56.5 years). It was then
170 separated into a 3-tier variable using the same categories as the childhood body size
171 measure; “thinner” (21.1kg/m^2 - 25kg/m^2), “about average” (25kg/m^2 - 31.7kg/m^2) and
172 “plumper” (31.7kg/m^2 - 59.9kg/m^2) (34, 35). Individuals that did not have data for both
173 childhood and adult body size were excluded from analyses and a genetic correlation
174 coefficient of $r_G=0.61$ was previously calculated between these two measures (36). In
175 addition, these scores have been independently validated in two distinct cohorts,
176 providing verification that these genetic instruments can reliably separate childhood and
177 adult body size. Furthermore, comparing the genetic correlation between the childhood
178 body size GWAS with a recent GWAS of measured childhood BMI, provided strong
179 evidence of validation using LD score regression ($r_g=0.96$) (37).

180

181 A previously published GWAS on individuals in the UK Biobank for the main outcome,
182 fractures in later life, was used (n=416,795) (38). This excluded fractures of the skull,
183 face, hands and feet, pathological fractures due to malignancy, atypical femoral
184 fractures, periprosthetic, and healed fracture codes and a full list of ICD10 codes used
185 have been reported previously (38). Effect estimates derived from results indicate an
186 additive change in the odds of each change in weight category in childhood and adult
187 body size (36). To generate genetic instruments for birthweight (n=261,932), GWAS
188 were undertaken on UK Biobank individuals with adjustment for age, sex and
189 genotyping chip. We used a linear mixed model to account for genetic relatedness and
190 geographical structure in UK Biobank as undertaken with the BOLT-LMM software.
191 Birthweight was kept as a continuous trait given that it was not available in the full
192 sample and rank-based inverse normal transformed, to ensure values lay within
193 accepted limits assuming a normal distribution. We additionally ran GWAS for several
194 potential mediators using UK Biobank data with the application of the same analysis
195 pipeline stipulated above. Mediators included genetic predisposition to increased serum
196 calcium in nmol/L (n=432,151), vitamin D level in nmol/L (n=449,913) and eBMD,
197 derived from heel ultrasound (n=278,932), in the total population, as well as bioavailable
198 testosterone (female n=206,604, male n=207,470), total testosterone (female
199 n=180,386, male n=184,025), and SHBG (female n=222,491, male n=205,646), in the
200 sex-stratified population. We standardised the distribution of these variables to have a
201 mean of 0 and standard deviation of 1 and results are quantified as standard deviation
202 change. In addition, in sensitivity analyses this study estimated effects on sex
203 (n=361,194) to assess participation bias, as well as total body fat mass (n=453,957) and
204 total body fat-free mass (n=454,669) which were made into indices by dividing by
205 height (m)² using UK Biobank data (S1 Table).

206
207 Conducting MR using overlapping sets of participant samples has been shown to bias in
208 the direction of the observational association between the risk factor and outcome (39).
209 We therefore used previously developed formulae implemented in a web application
210 (<https://sb452.shinyapps.io/overlap/>) to calculate expected bias and Type 1 error rate
211 under the null for genetically proxied childhood body size and odds of fracture in later

212 life (40). Data used to generate output is in S2 Table. Estimated bias due to sample
213 overlap is presented in S3 Table.

214

215

216 The UK Biobank study have obtained ethics approval from the Research Ethics
217 Committee (REC; approval number: 11/NW/0382) and informed consent from all
218 participants enrolled in UK Biobank. Estimates were derived using data from the UK
219 Biobank (app #76538).

220

221 Statistical analysis

222

223 Univariable MR was initially conducted to estimate the ‘total’ effects of genetically
224 predicted childhood body size and adult body size on fractures in later life. Firstly, the
225 inverse variance weighted method (IVW) was employed, which takes SNP-outcome
226 estimates and regresses them on the SNP-exposure associations (41). Complementary
227 methods, namely weighted median and MR-Egger were subsequently used to assess
228 the robustness of the univariable results obtained. This provided more robust to MR
229 assumptions compared to the IVW method, including horizontal pleiotropy, whereby
230 genetic variants influence multiple traits or disease outcomes via independent biological
231 pathways (42). Multivariable IVW MR was used to calculate the direct and indirect
232 effects of childhood body size and adult body size, simultaneously, on fractures in later
233 life, accounting for either adult body size or childhood body size, respectively i.e., the
234 exposure variables that were not considered the main exposure of interest, in each
235 model (24). Genetic estimates for our exposures were harmonized with mediators and
236 the disease outcome using the ‘TwoSampleMR’ R package. Forest plots in this paper
237 were generated using the R package ‘ggplot2’ (43). These analyses were undertaken
238 using R (version 3.5.1).

239

240 Birthweight was investigated as a third exposure related to body size in i) univariable
241 MR, assessing the ‘total’ effect of birthweight on the outcome, fractures in later life, ii)
242 multivariable MR assessing the ‘direct’ and ‘indirect’ effect of birthweight on the

243 outcome, by taking childhood and adult body size into account, and iii) in both childhood
244 and adult body size multivariable MR models, accounting for birthweight, to determine
245 whether any effects of childhood and adult body size observed are a result of weight in
246 very early life (44). A combination of foetal- and maternal-specific mechanisms and
247 tissues have been identified in the regulation of birthweight, with some mechanisms
248 involving directionally opposing effects in the foetus and mother (45). Therefore, this
249 investigation of birthweight was not to determine the effects of parental factors on
250 fracture risk in later life, but to exclude the possibility that very early life body size is an
251 explanation of the childhood BMI effect.

252

253 *Two-step Mendelian Randomization*

254

255 To investigate the possible mechanisms by which body size affects fractures and
256 determine potential intermediate traits, two-step MR was conducted (26). This was
257 achieved by, i) assessing the separate effects of genetically predicted childhood body
258 size and adult body size on each of the potential non-sex-specific mediators; eBMD,
259 calcium, and vitamin D, as outcomes, and then, ii) assessing each of these mediators
260 as exposures on the outcome, fractures in later life. Multivariable IVW MR analyses
261 were additionally computed to calculate the direct and indirect effects of childhood body
262 size and adult body size, simultaneously, on mediators of interest.

263

264 *Sex-stratification*

265

266 Univariable and multivariable MR analyses were conducted in sex-stratified groups;
267 female or male, assigned at birth. Two-sample MR was subsequently computed to
268 investigate bioavailable testosterone, total testosterone, and SHBG, to determine any
269 potential hormonal sex-specific mechanisms of action between body size and eBMD as
270 well as fractures in later life.

271

272 Sensitivity analyses

273

274 *Body composition measures*

275

276 To establish whether results indicate a true causal effect of childhood body size, that
277 does not discriminate between adiposity and lean mass, on fracture risk in later life, we
278 explored the effects of childhood and adult body size on fat mass index and fat-free
279 mass index in a univariable and multivariable MR setting. In addition, we conducted
280 multivariable MR analyses to assess the relationship between childhood body size and
281 fracture risk in later life, accounting for fat mass index and fat-free mass index to
282 estimate potential mediation. This was also to maintain an estimate with suitable
283 comparability to the adult measure used (a genetic proxy for BMI).

284

285 *Sex-differential participation bias*

286

287 We investigate the potential for artefactual associations as a result of sex-differential
288 participation, whereby childhood or adult body size may have led males and females to
289 differentially participate in the UK Biobank study. This was achieved through estimating
290 variants associated with the traits, childhood and adult body size, and sex (46).

291

292 *Family-based analyses*

293


294 Findings from MR analyses of unrelated individuals may be biased as a result of
295 uncontrolled confounding from familial effects: dynastic effects, assortative mating, or
296 population stratification (47). It has been argued that within-family genetic association
297 estimates, for example, those acquired from samples of siblings, may allow more
298 accurate estimates of direct genetic effects since these are unaffected by demography
299 and indirect genetic effects of parents (48). Population (between-family) and within-
300 sibship (within-family) estimates (n=39,507) were therefore generated to ensure the
301 direction of our estimates were not a result of dynastic effects, assortative mating, or
302 population stratification.

303

304 **Results**

305
306 Univariable analyses indicated evidence that higher genetically predicted childhood
307 body size reduced the odds of fractures in later life (IVW OR, 95% CI: 0.89, 0.82 to
308 0.96, $P=0.005$). Multivariable MR analyses showed strong evidence of an effect
309 between higher genetically predicted childhood body size and fractures in later life, after
310 accounting for adult body size (OR, 95% CI: 0.76, 0.69 to 0.85, $P=1 \times 10^{-6}$). There was
311 some evidence of an association between higher genetically predicted adult body size
312 and the odds of fractures in later life (OR, 95% CI: 1.08, 1.01 to 1.16, $P=0.023$). There
313 was additionally strong evidence of an effect between higher genetically predicted adult
314 body size and fractures in later life, after accounting for childhood body size (OR, 95%
315 CI: 1.26, 1.14 to 1.38, $P=2 \times 10^{-6}$) (Table 1, Figure 2). Consistent patterns of association
316 were apparent when using the weighted median method employed for robustness in
317 univariable analyses. Results using the MR-Egger method did not provide evidence that
318 horizontal pleiotropy was driving these effects in childhood, with effect estimates similar
319 when using the IVW method, however, those for adult body size demonstrated the
320 reverse direction of effect, suggesting the effect of adult body size may be prone to
321 horizontal pleiotropy (Table 1).

322



323
324 **Figure 2. Univariable and multivariable Mendelian randomization for childhood**
325 **and adult body size onto the outcome measure, fractures in later life.** Dots filled-in
326 indicate some to very strong statistical evidence of an association.

327


328 In univariable analyses, there was some evidence of an effect between genetically
329 predicted higher birthweight and increase in fractures in later life (OR, 95% CI: 1.08,
330 1.01 to 1.16, $P=0.036$). In multivariable analyses, there was evidence of an effect
331 between genetically predicted higher birthweight and increase in fractures in later life
332 (OR, 95% CI: 1.03, 1.01 to 1.17, $P=0.003$), accounting for childhood and adult body
333 size. There was strong evidence of an effect between childhood body size and fractures
334 in later life, after accounting for adult body size and birthweight (OR, 95% CI: 0.78, 0.69
335 to 0.88, $P=7 \times 10^{-5}$). There was additionally strong evidence of an effect between adult
336 body size and fractures in later life (OR, 95% CI: 1.21, 1.09 to 1.35, $P=3 \times 10^{-4}$), after
337 accounting for childhood body size and birthweight (Table 2).

338

339 *Two-step Mendelian randomization*

340


341 Among the mediators assessed in the total population, strong evidence of an effect was
342 observed in both MR steps for childhood and adult body size and eBMD. An increase
343 per one standard deviation in genetically predicted childhood and adult body size
344 indicated an increase in eBMD (beta, 95% CI: 0.26, 0.20 to 0.33, $P=3 \times 10^{-16}$ and 0.20,
345 0.16 to 0.25, $P=1 \times 10^{-17}$, respectively). In multivariable MR, the effect estimate slightly
346 weakened when estimating childhood body size on eBMD (beta, 95% CI: 0.20, 0.12 to
347 0.27, $P=3 \times 10^{-7}$) and substantially when estimating adult body size on eBMD (beta, 95%
348 CI: 0.09, 0.02 to 0.15, $P=0.008$) (Figure 3). In addition, an increase in eBMD
349 demonstrated a decrease in fractures in later life (OR, 95% CI: 0.62, 0.60 to 0.64,
350 $P=5 \times 10^{-150}$) (Table 3).



351

352 **Figure 3. Univariable and multivariable Mendelian randomization for childhood**
353 **and adult body size onto estimated bone mineral density.** Dots filled-in indicate
354 some to very strong statistical evidence of an association.

355
356 There was strong evidence of an association between genetically predicted childhood
357 body size and calcium (beta, 95% CI: -0.11, -0.15 to -0.06, $P=6 \times 10^{-7}$), and evidence of
358 an effect between genetically predicted adult body size and calcium (beta, 95% CI: -
359 0.05, -0.09 to -0.01, $P=0.006$), however, little evidence of an association between
360 calcium and fractures in later life (OR, 95% CI: 0.99, 0.95 to 1.04, $P=0.813$).
361 Furthermore, there was strong evidence of an effect between genetically predicted
362 childhood and adult body size on vitamin D (beta, 95% CI: -0.07, -0.10 to -0.04, $P=5 \times 10^{-5}$
363 and -0.18, -0.21 to -0.16, $P=1 \times 10^{-37}$) and little evidence of an effect between vitamin D
364 and fractures in later life (OR, 95% CI: 1.02, 0.96 to 1.09, $P=0.541$) (Table 3, Figure 4).
365




366
367 **Figure 4. Two-step mendelian randomization results estimating (A) childhood**
368 **body size on selected mediators and (B) selected mediators onto the outcome**
369 **measure, fractures in later life, in the total population.** Dots filled-in indicate some to
370 very strong statistical evidence of an association.

371
372 *Sex-stratification*

373
374 Upon stratification, there was strong evidence of an association between childhood
375 body size and eBMD in females (beta, 95% CI: 0.18, 0.10 to 0.26, $P=7 \times 10^{-6}$) and in
376 males (beta, 95% CI: 0.36, 0.23 to 0.49, $P=3 \times 10^{-8}$). After accounting for adult body size,
377 there remained evidence of an increase in eBMD with central effect estimates more
378 comparable between females and males (beta, 95% CI: 0.21, 0.13 to 0.29, $P=5 \times 10^{-7}$)

379 and beta, 95% CI: 0.20, 0.05 to 0.346, $P=0.008$, respectively). There was additionally
380 strong evidence of an increase in eBMD and decrease in fractures in later life in females
381 (OR, 95% CI: 0.60, 0.57 to 0.63, $P=2 \times 10^{-112}$) and males (OR, 95% CI: 0.69, 0.65 to
382 0.73, $P=5 \times 10^{-40}$) (Table 3). Consistent patterns of associations were observed using the
383 weighted median method employed for robustness. In addition, results using the MR-
384 Egger method did not provide evidence that horizontal pleiotropy was responsible for
385 the estimates derived. Two-sample MR estimates computed to investigate bioavailable
386 testosterone, total testosterone, and SHBG, as potential mechanisms of action between
387 body size and fractures in later life are presented in Figure 5. Further estimates from
388 two-sample analyses, including those which account for adult body size, are presented
389 in S4 Table.
390



391
392
393 **Figure 5. Two-step mendelian randomization results estimating (A) childhood**
394 **body size on selected mediators and (B) selected mediators onto the outcome**
395 **measure, fractures in later life, sex stratified.** Dots filled-in indicate some to very
396 strong statistical evidence of an association.

397
398 Sensitivity analyses

399
400 *Body composition measures*

401
402 There was strong evidence of an effect between childhood and adult body size and fat-
403 free mass index, measured in adulthood (beta, 95% CI: 0.75, 0.69 to 0.792 $P=3 \times 10^{-195}$
404 and 1.00, 0.98 to 1.02, $P=1 \times 10^{-300}$, respectively). Consistent patterns of associations

405 were observed using the weighted median method employed for robustness and results
406 using the MR-Egger method did not provide evidence that horizontal pleiotropy was
407 responsible for the derived estimates (S5 Table). In multivariable MR analyses, whilst
408 the beta reduced, there remained strong evidence of an association between genetically
409 predicted childhood body size and fat-free mass index, after accounting for adult body
410 size (beta, 95% CI: 0.18, 0.14 to 0.21, $P=8 \times 10^{-23}$). There was additionally strong
411 evidence of an effect between higher genetically predicted adult body size and an
412 increase in fat-free mass index, after accounting for childhood body size (beta, 95% CI:
413 0.91, 0.88 to 0.94, $P=1 \times 10^{-300}$). Furthermore, in univariable analyses, there was strong
414 evidence of an effect between higher childhood and adult body size and increased fat
415 mass index, measured in adulthood (beta, 95% CI: 0.78, 0.72 to 0.84, $P=7 \times 10^{-154}$ and
416 1.30, 1.29 to 1.32, $P < 1 \times 10^{-300}$, respectively). In multivariable MR after accounting for
417 adult body size, there was strong evidence of an effect between higher genetically
418 predicted childhood body size and reduced fat mass index (beta, 95% CI: -0.05, -0.08 to
419 -0.02, $P=5 \times 10^{-4}$). There remained strong evidence of an effect between higher
420 genetically predicted adult body size and increase in fat mass index, after accounting for
421 childhood body size (beta, 95% CI: 1.33, 1.30 to 1.35, $P=1 \times 10^{-300}$). Further estimates,
422 including those stratified by sex, are in S5 Table.

423
424 The relationship between childhood body size and the odds of fracture in later life
425 increased marginally, after accounting for lean mass index (OR, 95% CI: 0.82, 0.73 to
426 0.92, $P=0.001$) and reduced after accounting for fat mass index (OR, 95% CI: 0.76, 0.68
427 to 0.84, $P=0.008$) (S6 Table). This suggests that the childhood body size measure used
428 in this analysis does not discriminate between adiposity and lean mass.

429
430 *Sex-differential participation bias*

431
432 There was evidence of an association between childhood and adult body size on sex.
433 For example, results indicate that childhood and adult body size reduced the odds of
434 being female (OR, 95% CI: 0.94, 0.89 to 0.99, $P=0.029$ and OR, 95% CI: 0.96, 0.91 to

435 1.00, $P=0.049$, respectively) (S7 Table). These artifactual relationships observed
436 suggest some sex-differential participation bias is apparent.

437

438 *Family-based analyses*

439

440 Between-family univariable and multivariable estimates reveal consistent directions of
441 effect with estimates from the whole population. Results are underpowered, however.
442 This is due to i) the large reduction in the sample size, from the whole population
443 ($n=501,550$) to a subset of siblings in the UK Biobank ($n=39,507$) and ii) there being
444 difference in genetics in between-sibling analyses (S8 Table).

445

446 **Discussion**

447

448 In this MR study, we employed a lifecourse framework to evaluate the effects of
449 genetically proxied childhood and adult body size on fractures in later life. We observed
450 strong evidence of an effect between higher childhood body size and reduced fracture
451 risk in later life. This association became stronger after accounting for adult body size.
452 Conversely, we identified a strong causal effect of adult body size on an increase in the
453 odds of fracture in univariable as well as multivariable analyses, after accounting for
454 childhood body size. Findings from this study suggest that higher body size in childhood
455 may have a lasting influence on fracture risk in later life and therefore, the protective
456 effect estimates observed in previous clinical and observational epidemiological
457 research between BMI in adults and fracture risk (12, 13), are likely attributed to
458 childhood effects. Where greater body size leads to an adaptive change in bone size
459 and strength during growth, our results suggest that this does not occur in later life once
460 growth has ceased. Importantly, the childhood body size measure used in this
461 investigation does not discriminate between adipose and lean mass, or between fat
462 stored in different compartments of the body. Furthermore, investigating birthweight as
463 a third exposure showed that the effects of childhood and adult body size observed
464 were not a result of body size at birth.

465

466 We additionally investigated whether plausible risk factors for fractures served as
467 intermediate variables (mediators) on the causal pathway between childhood body size
468 and fracture risk in later life, using two-step MR. Genetically predicted childhood body
469 size was strongly associated with a decrease in calcium and vitamin D levels and an
470 increase in eBMD in adulthood. There was, however, very little evidence of an effect
471 between vitamin D and calcium on the odds of fracture in later life. On the other hand,
472 we observed a strong causal association between eBMD and a decrease in the odds of
473 fracture risk. Indeed, adiposity in childhood has been shown previously to be causally
474 related to BMD in childhood, specifically of the limbs, pelvis, and spine, and not the skull
475 (16). One hypothesis is that this reflects the positive effects of loading on bone
476 formation at weighted sites. The effect we show between childhood body size and
477 eBMD suggests that body size affects the amount of trabecular bone. As well as there
478 being a scaling relationship between body size and overall bone size during growth, the
479 internal bone structure is positively influenced by body size. This appears to persist
480 throughout life, protecting against fracture risk regardless of BMI reduction in adulthood.
481 In addition, whilst calcium and vitamin D supplementation is recommended for fracture
482 prevention (49-51), findings from randomised clinical trials yield conflicting conclusions
483 regarding their efficacy (52-54). Our results are supported by a recent MR study
484 showing that genetic predisposition to lower levels of vitamin D and estimated calcium
485 intake from dairy sources did not appear to be associated with fracture risk (19).
486 Furthermore, MR investigations have shown that genetic evidence of increased serum
487 calcium levels did not improve eBMD (55, 56).

488
489 Since effects of body weight are often sex-specific (27), we investigated the relationship
490 between childhood body size and fracture risk as well as childhood body size and
491 eBMD, separately by sex. The strength of the genetically predicted effect of childhood
492 body size in males compared to females was more than 2-fold in magnitude on both
493 outcome measures. Upon accounting for adult body size, these differences diminished,
494 suggesting that our adult body size measure was, to a large degree, responsible for the
495 sex differences observed in the outcomes of interest. Furthermore, higher childhood
496 body size was strongly associated with a decrease of bioavailable testosterone in males

497 and increase in females. This finding is supported by the literature, whereby obese
498 males have been characterised by a decrease in testosterone levels with increasing
499 body weight (57). Their female counterparts, conversely, have been shown to develop a
500 condition of functional hyperandrogenism (58), which is, in most cases, detectable by
501 testosterone elevation (57). Reduced SHBG synthesis and circulating blood levels have
502 also been shown to represent the sole common mechanism response for this in both
503 males and females (57), with the former observed in our findings as additionally
504 occurring in response to higher body size in childhood. There was also strong evidence
505 that bioavailable testosterone reduced the risk of fractures in both males and females.
506 These associations, again, were stronger in males than they were in females.
507 Furthermore, since the sex hormone measures used in this study were quantified in an
508 adult population (mean age: 56.5 years), it is likely their effect is more strongly related to
509 adult body size. This is in line with the literature, which has shown age-related
510 testosterone deficiency to be the most important factor of bone loss in elderly men (59)
511 and that SHBG in midlife is linked with injury risk in both sexes (28). It is additionally
512 plausible, that the sex-differential associations observed in this study are, in part, a
513 result of sex-differential participation bias, where the determinants of study participation
514 affect females and males to differing extents (46). Evidence of this has been shown
515 where artifactual associations between variants associated with childhood and adult
516 body size and sex were observed.

517
518 From a public health perspective, the relationship between BMI and fracture risk is
519 complex, as obesity remains a major risk factor for co-morbidities, including diabetes,
520 cardiovascular diseases, cancer, and other health problems that may lead to further
521 morbidity and mortality (60). It is nevertheless of importance to quantify the effect of BMI
522 at different stages in the lifecourse on the risk of fracture in later life, to help i) identify
523 modifiable pathways to fracture risk to decipher potential intervention targets, and ii)
524 enhance the predictive value of BMI at different time points in fracture risk case finding
525 (13, 60). In addition, this investigation highlights the importance of processes operating
526 across the lifecourse, that influence the development of risk in later life (61).

527

528 Strengths and limitations:

529

530 Investigations have previously assessed the relationship between BMI and fracture risk
531 observationally, as well as cross-sectionally, using MR methods. This is a unique study
532 in that it estimates the effects of body size on fracture risk at separate timepoints in the
533 lifecourse, whilst inferring causality by utilising the relationship between genetic variants
534 robustly associated with a modifiable exposure or biological intermediate of interest and
535 a disease outcome. An important and perhaps underreported methodological limitation
536 in much of the obesity literature is through the use of BMI as an imperfect measure of
537 adiposity (23). Whilst BMI indicates overweight relative to height, it does not
538 discriminate between adiposity and lean mass. This study explores this measure to
539 conclude that it is both indicative of adiposity and lean mass. This study additionally
540 revealed potential mediators on the causal pathway between childhood body size and
541 fracture risk, to aid in the identification of prospective intervention targets that may help
542 to reduce fracture risk in later life. Furthermore, this investigation was able to leverage
543 large sample sizes available through the UK Biobank study (n=453,169) for all
544 measures used, by calculating expected bias and Type 1 error rate under the null that
545 could result from using overlapping samples. In addition, weighted median and MR-
546 Egger methods were used to assess the robustness of univariable results to horizontal
547 pleiotropy.

548

549 This study, however, also has important limitations. First, self-reporting of body size in
550 childhood by participants may have led to differential social desirability bias, in relation
551 to retrospective weight recall at age 10. Moreover, the age of participants in adulthood
552 when reporting this information could have influenced this measurement. To account for
553 this, GWAS were computed on individuals who had both measures available adjusting
554 for age, as well as sex and the genotyping chip. Second, our measure of childhood
555 body size did not discriminate between adipose and lean mass, nor did it between fat
556 stored in different compartments of the body. Third, using sex hormones quantified in
557 adulthood, as opposed to childhood, where sex hormone levels are substantially
558 different, limited our ability to decipher potentially important mechanisms between

559 childhood body size and sex hormone regulation at the same timepoint. We additionally
560 used fat and lean mass measures from adulthood, which likely associated more strongly
561 with adult BMI than childhood as a result. Fourth, in using the UK Biobank, selection
562 bias is a central limitation. Participation in the UK Biobank has been shown to be
563 associated with being older, female and living in areas that are less likely to be
564 socioeconomically deprived than individuals in nationally representative data sources
565 (62). Therefore, this analysis is under-representative of younger, male, non-binary or
566 any other gender identity individuals as well as those from the lowest socioeconomic
567 position group. This has the potential to result in problems for instrumental variable
568 analyses (63). In addition, we have shown that our sex-stratified results may, in part,
569 exhibit artefactual autosomal heritability in the presence of sex-differential participation
570 bias, which has been shown to lead to incorrect inferences in downstream analyses
571 (46). Moreover, since allele frequencies as well as risk factors and diseases vary
572 between subgroups in the population, confounding is plausible. This study thus
573 performs analyses in homogeneous populations of European ancestry (64), therefore
574 only depicting effects within this single ancestry group that may not be generalisable to
575 other ancestry populations. Future research would benefit from replicating this across a
576 broader range of different ancestries.

577

578 **Conclusions:**

579

580 This investigation provides novel evidence that genetically proxied childhood body size
581 has a direct effect on reduced fractures in later life, via increased eBMD. Importantly,
582 findings additionally indicate that higher BMI in adulthood is indeed a risk factor for
583 fractures, opposing earlier clinical and epidemiological observational research findings
584 which denote it as protective. The protective effect estimates previously observed
585 between BMI in adults and fracture risk are therefore likely attributed to childhood
586 effects.

587 **Acknowledgements**

588

589 We would like to thank the UK Biobank study and all participants who contributed to it,
590 as well as the authors of all the GWAS who made their summary statistics available for
591 the benefit of this work. Estimates on childhood and adult body size were derived
592 previously using data from the UK Biobank (app #15825).

593

594 **Financial Disclosure Statement**

595

596 This work was in part supported by the Integrative Epidemiology Unit which receives
597 funding from the UK Medical Research Council and the University of Bristol
598 (MC_UU_00011/1). GDS conducts research at the NIHR Biomedical Research Centre
599 at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol.
600 The views expressed in this publication are those of the author(s) and not necessarily
601 those of the NHS, the National Institute for Health Research or the Department of
602 Health. GMP is supported by the GW4 Biomed Doctoral Training Programme, awarded
603 to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research
604 Council (MRC)/UKRI (MR/N0137941/1). TGR was a UKRI Innovation Research Fellow
605 whilst contributing to this study (MR/S003886/1). TMF has received funding from the
606 Medical Research Council (MR/T002239/1) EU-IMI SOPHIA and GSK. JT is supported
607 by an Academy of Medical Sciences (AMS) Springboard award, which is supported by
608 the AMS, the Wellcome Trust, GCRF, the Government Department of Business, Energy
609 and Industrial strategy, the British Heart Foundation and Diabetes UK (SBF004\1079).
610 The funders had no role in study design, data collection and analysis, decision to
611 publish, or preparation of the manuscript.

612

613

614 **References:**

615

- 616 1. Csuhai É A, Nagy AC, Szöllősi GJ, Veres-Balajti I. Impact Analysis of 20-Week
617 Multimodal Progressive Functional-Proprioceptive Training among Sedentary Workers
618 Affected by Non-Specific Low-Back Pain: An Interventional Cohort Study. *Int J Environ*
619 *Res Public Health*. 2021;18(20).
- 620 2. Pineles SL, Repka MX, Yu F, Lum F, Coleman AL. Risk of musculoskeletal
621 injuries, fractures, and falls in medicare beneficiaries with disorders of binocular vision.
622 *JAMA Ophthalmol*. 2015;133(1):60-5.
- 623 3. Johnell O. The socioeconomic burden of fractures: today and in the 21st century.
624 *Am J Med*. 1997;103(2a):20S-5S; discussion 5S-6S.
- 625 4. Zhao JG, Zeng XT, Wang J, Liu L. Association Between Calcium or Vitamin D
626 Supplementation and Fracture Incidence in Community-Dwelling Older Adults: A
627 Systematic Review and Meta-analysis. *Jama*. 2017;318(24):2466-82.
- 628 5. Zheng R, Byberg L, Larsson SC, Höijer J, Baron JA, Michaëlsson K. Prior loss of
629 body mass index, low body mass index, and central obesity independently contribute to
630 higher rates of fractures in elderly women and men. *J Bone Miner Res*.
631 2021;36(7):1288-99.
- 632 6. Baxter-Jones AD, Faulkner RA, Forwood MR, Mirwald RL, Bailey DA. Bone
633 mineral accrual from 8 to 30 years of age: an estimation of peak bone mass. *J Bone*
634 *Miner Res*. 2011;26(8):1729-39.
- 635 7. Tella SH, Gallagher JC. Prevention and treatment of postmenopausal
636 osteoporosis. *J Steroid Biochem Mol Biol*. 2014;142:155-70.
- 637 8. Farr JN, Khosla S. Skeletal changes through the lifespan--from growth to
638 senescence. *Nat Rev Endocrinol*. 2015;11(9):513-21.
- 639 9. Siervogel RM, Demerath EW, Schubert C, Remsberg KE, Chumlea WC, Sun S,
640 et al. Puberty and body composition. *Horm Res*. 2003;60(Suppl 1):36-45.
- 641 10. Schutz Y, Kyle UU, Pichard C. Fat-free mass index and fat mass index
642 percentiles in Caucasians aged 18-98 y. *Int J Obes Relat Metab Disord*.
643 2002;26(7):953-60.
- 644 11. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005
645 and projections to 2030. *Int J Obes (Lond)*. 2008;32(9):1431-7.
- 646 12. Johansson H, Kanis JA, Odén A, McCloskey E, Chapurlat RD, Christiansen C, et
647 al. A meta-analysis of the association of fracture risk and body mass index in women. *J*
648 *Bone Miner Res*. 2014;29(1):223-33.
- 649 13. De Laet C, Kanis JA, Odén A, Johanson H, Johnell O, Delmas P, et al. Body
650 mass index as a predictor of fracture risk: a meta-analysis. *Osteoporos Int*.
651 2005;16(11):1330-8.
- 652 14. Palermo A, Tuccinardi D, Defeudis G, Watanabe M, D'Onofrio L, Lauria Pantano
653 A, et al. BMI and BMD: The Potential Interplay between Obesity and Bone Fragility. *Int J*
654 *Environ Res Public Health*. 2016;13(6):544.
- 655 15. Gonnelli S, Caffarelli C, Nuti R. Obesity and fracture risk. *Clin Cases Miner Bone*
656 *Metab*. 2014;11(1):9-14.
- 657 16. Kemp JP, Sayers A, Smith GD, Tobias JH, Evans DM. Using Mendelian
658 randomization to investigate a possible causal relationship between adiposity and

- 659 increased bone mineral density at different skeletal sites in children. *Int J Epidemiol.*
660 2016;45(5):1560-72.
- 661 17. Richmond RC, Davey Smith G. Mendelian Randomization: Concepts and Scope.
662 Cold Spring Harbor Perspectives in Medicine. 2021.
- 663 18. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology
664 contribute to understanding environmental determinants of disease? *Int J Epidemiol.*
665 2003;32(1):1-22.
- 666 19. Trajanoska K, Morris JA, Oei L, Zheng H-F, Evans DM, Kiel DP, et al.
667 Assessment of the genetic and clinical determinants of fracture risk: genome wide
668 association and mendelian randomisation study. *BMJ.* 2018;362:k3225.
- 669 20. Clark EM, Ness AR, Tobias JH. Adipose tissue stimulates bone growth in
670 prepubertal children. *The Journal of clinical endocrinology and metabolism.*
671 2006;91(7):2534-41.
- 672 21. Timpson NJ, Sayers A, Davey-Smith G, Tobias JH. How does body fat influence
673 bone mass in childhood? A Mendelian randomization approach. *J Bone Miner Res.*
674 2009;24(3):522-33.
- 675 22. Turner CH, Forwood MR, Rho JY, Yoshikawa T. Mechanical loading thresholds
676 for lamellar and woven bone formation. *J Bone Miner Res.* 1994;9(1):87-97.
- 677 23. Lee DH, Keum N, Hu FB, Orav EJ, Rimm EB, Willett WC, et al. Predicted lean
678 body mass, fat mass, and all cause and cause specific mortality in men: prospective US
679 cohort study. *BMJ.* 2018;362:k2575.
- 680 24. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of
681 multivariable Mendelian randomization in the single-sample and two-sample summary
682 data settings. *Int J Epidemiol.* 2019;48(3):713-27.
- 683 25. Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of
684 pleiotropic genetic variants to estimate causal effects. *Am J Epidemiol.*
685 2015;181(4):251-60.
- 686 26. Relton CL, Davey Smith G. Two-step epigenetic Mendelian randomization: a
687 strategy for establishing the causal role of epigenetic processes in pathways to disease.
688 *Int J Epidemiol.* 2012;41(1):161-76.
- 689 27. Rask-Andersen M, Karlsson T, Ek WE, Johansson Å. Genome-wide association
690 study of body fat distribution identifies adiposity loci and sex-specific genetic effects. *Nat*
691 *Commun.* 2019;10(1):339.
- 692 28. Leinonen JT, Mars N, Lehtonen LE, Ahola-Olli A, Ruotsalainen S, Lehtimäki T, et
693 al. Genetic analyses on the health impacts of testosterone highlight effects on female-
694 specific diseases and sex differences. *medRxiv.* 2021:2021.04.23.21255981.
- 695 29. Eriksson J, Haring R, Grarup N, Vandenput L, Wallaschofski H, Lorentzen E, et
696 al. Causal relationship between obesity and serum testosterone status in men: A bi-
697 directional mendelian randomization analysis. *PLoS One.* 2017;12(4):e0176277.
- 698 30. Mohammadi-Shemirani P, Chong M, Pigeyre M, Morton RW, Gerstein HC, Paré
699 G. Effects of lifelong testosterone exposure on health and disease using Mendelian
700 randomization. *Elife.* 2020;9.
- 701 31. Ruth KS, Day FR, Tyrrell J, Thompson DJ, Wood AR, Mahajan A, et al. Using
702 human genetics to understand the disease impacts of testosterone in men and women.
703 *Nat Med.* 2020;26(2):252-8.

- 704 32. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank:
705 an open access resource for identifying the causes of a wide range of complex diseases
706 of middle and old age. *PLoS Med*. 2015;12(3):e1001779.
- 707 33. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK
708 Biobank resource with deep phenotyping and genomic data. *Nature*.
709 2018;562(7726):203-9.
- 710 34. Brandkvist M, Bjørngaard JH, Ødegård RA, Åsvold BO, Smith GD, Brumpton B,
711 et al. Separating the genetics of childhood and adult obesity: a validation study of
712 genetic scores for body mass index in adolescence and adulthood in the HUNT Study.
713 *Hum Mol Genet*. 2021;29(24):3966-73.
- 714 35. Richardson TG, Mykkänen J, Pahkala K, Ala-Korpela M, Bell JA, Taylor K, et al.
715 Evaluating the direct effects of childhood adiposity on adult systemic metabolism: a
716 multivariable Mendelian randomization analysis. *Int J Epidemiol*. 2021.
- 717 36. Richardson TG, Sanderson E, Elsworth B, Tilling K, Davey Smith G. Use of
718 genetic variation to separate the effects of early and later life adiposity on disease risk:
719 mendelian randomisation study. *BMJ*. 2020;369:m1203.
- 720 37. Vogelezang S, Bradfield JP, Ahluwalia TS, Curtin JA, Lakka TA, Grarup N, et al.
721 Novel loci for childhood body mass index and shared heritability with adult
722 cardiometabolic traits. *PLoS Genet*. 2020;16(10):e1008718.
- 723 38. Morris JA, Kemp JP, Youlten SE, Laurent L, Logan JG, Chai RC, et al. An atlas
724 of genetic influences on osteoporosis in humans and mice. *Nat Genet*. 2019;51(2):258-
725 66.
- 726 39. Nelson CR, Startz R. The Distribution of the Instrumental Variables Estimator
727 and Its t-Ratio When the Instrument is a Poor One. *The Journal of Business*.
728 1990;63(1):S125-S40.
- 729 40. Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-
730 sample Mendelian randomization. *Genet Epidemiol*. 2016;40(7):597-608.
- 731 41. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with
732 multiple genetic variants using summarized data. *Genet Epidemiol*. 2013;37(7):658-65.
- 733 42. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
734 instruments: effect estimation and bias detection through Egger regression. *Int J*
735 *Epidemiol*. 2015;44(2):512-25.
- 736 43. Ginestet C. ggplot2: Elegant Graphics for Data Analysis. *J R Stat Soc a Stat*.
737 2011;174:245-.
- 738 44. Yu XH, Wei YY, Zeng P, Lei SF. Birth weight is positively associated with adult
739 osteoporosis risk: observational and Mendelian randomization studies. *J Bone Miner*
740 *Res*. 2021;36(8):1469-80.
- 741 45. Warrington NM, Beaumont RN, Horikoshi M, Day FR, Helgeland Ø, Laurin C, et
742 al. Maternal and fetal genetic effects on birth weight and their relevance to cardio-
743 metabolic risk factors. *Nat Genet*. 2019;51(5):804-14.
- 744 46. Pirastu N, Cordioli M, Nandakumar P, Mignogna G, Abdellaoui A, Hollis B, et al.
745 Genetic analyses identify widespread sex-differential participation bias. *Nat Genet*.
746 2021;53(5):663-71.
- 747 47. Brumpton B, Sanderson E, Heilbron K, Hartwig FP, Harrison S, Vie G, et al.
748 Avoiding dynastic, assortative mating, and population stratification biases in Mendelian
749 randomization through within-family analyses. *Nat Commun*. 2020;11(1):3519.

- 750 48. Howe LJ, Nivard MG, Morris TT, Hansen AF, Rasheed H, Cho Y, et al. Within-
751 sibship GWAS improve estimates of direct genetic effects. *bioRxiv*.
752 2021:2021.03.05.433935.
- 753 49. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The
754 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of
755 Medicine: what clinicians need to know. *J Clin Endocrinol Metab*. 2011;96(1):53-8.
- 756 50. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or
757 calcium in combination with vitamin D supplementation to prevent fractures and bone
758 loss in people aged 50 years and older: a meta-analysis. *Lancet*. 2007;370(9588):657-
759 66.
- 760 51. Bischoff-Ferrari HA, Willett WC, Orav EJ, Lips P, Meunier PJ, Lyons RA, et al. A
761 pooled analysis of vitamin D dose requirements for fracture prevention. *N Engl J Med*.
762 2012;367(1):40-9.
- 763 52. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, et al.
764 Calcium plus vitamin D supplementation and the risk of fractures. *N Engl J Med*.
765 2006;354(7):669-83.
- 766 53. Porthouse J, Cockayne S, King C, Saxon L, Steele E, Aspray T, et al.
767 Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin
768 D3) for prevention of fractures in primary care. *BMJ*. 2005;330(7498):1003.
- 769 54. Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S, et al.
770 Combined calcium and vitamin D3 supplementation in elderly women: confirmation of
771 reversal of secondary hyperparathyroidism and hip fracture risk: the Decalys II study.
772 *Osteoporos Int*. 2002;13(3):257-64.
- 773 55. Sun JY, Zhang H, Zhang Y, Wang L, Sun BL, Gao F, et al. Impact of serum
774 calcium levels on total body bone mineral density: A mendelian randomization study in
775 five age strata. *Clin Nutr*. 2021;40(5):2726-33.
- 776 56. Cerani A, Zhou S, Forgetta V, Morris JA, Trajanoska K, Rivadeneira F, et al.
777 Genetic predisposition to increased serum calcium, bone mineral density, and fracture
778 risk in individuals with normal calcium levels: mendelian randomisation study. *BMJ*.
779 2019;366:l4410.
- 780 57. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome
781 (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.
782 *Endocr Rev*. 2016;37(5):467-520.
- 783 58. Pasquali R. Obesity and androgens: facts and perspectives. *Fertil Steril*.
784 2006;85(5):1319-40.
- 785 59. Mohamad N-V, Soelaiman I-N, Chin K-Y. A concise review of testosterone and
786 bone health. *Clin Interv Aging*. 2016;11:1317-24.
- 787 60. Chan RSM, Woo J. Prevention of overweight and obesity: how effective is the
788 current public health approach. *Int J Environ Res Public Health*. 2010;7(3):765-83.
- 789 61. Kuh D, Ben-Shlomo Y, Lynch J, Hallqvist J, Power C. Life course epidemiology. *J*
790 *Epidemiol Community Health*. 2003;57(10):778-83.
- 791 62. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al.
792 Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank
793 Participants With Those of the General Population. *Am J Epidemiol*. 2017;186(9):1026-
794 34.

- 795 63. Hughes RA, Davies NM, Davey Smith G, Tilling K. Selection Bias When
796 Estimating Average Treatment Effects Using One-sample Instrumental Variable
797 Analysis. *Epidemiology*. 2019;30(3):350-7.
- 798 64. Sekula P, Del Greco MF, Pattaro C, Köttgen A. Mendelian Randomization as an
799 Approach to Assess Causality Using Observational Data. *J Am Soc Nephrol*.
800 2016;27(11):3253-65.
801
802

803 **Table 1.** Univariable and multivariable Mendelian randomization analyses for childhood
 804 and adult body size onto fracture risk in later life
 805
 806

Exposure	nSNPs*	Beta	Standard error	p value	Odds ratio (95% confidence interval)	Mendelian randomization (MR)	Method	Sex
Childhood body size	313	-0.12	0.04	5E-03	0.89 (0.82, 0.96)	Univariable MR	Inverse variance weighted	All
Childhood body size	313	-0.08	0.06	2E-01	0.92 (0.82, 1.04)	Univariable MR	Weighted Median	All
Childhood body size	313	-0.13	0.10	2E-01	0.88 (0.73, 1.06)	Univariable MR	MR-Egger Inverse variance weighted	All
Adult body size	580	0.08	0.03	2E-02	1.08 (1.01, 1.16)	Univariable MR	Inverse variance weighted	All
Adult body size	580	0.06	0.05	3E-01	1.06 (0.96, 1.17)	Univariable MR	Weighted Median	All
Adult body size	580	-0.11	0.10	3E-01	0.90 (0.74, 1.09)	Univariable MR	MR-Egger Inverse variance weighted	All
Childhood body size	142	-0.07	0.07	3E-01	0.94 (0.82, 1.06)	Univariable MR	Inverse variance weighted	Female
Childhood body size	142	-0.10	0.09	3E-01	0.91 (0.76, 1.08)	Univariable MR	Weighted Median	Female
Childhood body size	142	-0.01	0.15	9E-01	0.99 (0.74, 1.33)	Univariable MR	MR-Egger Inverse variance weighted	Female
Adult body size	221	0.06	0.06	2E-01	1.06 (0.95, 1.19)	Univariable MR	Inverse variance weighted	Female
Adult body size	221	0.07	0.08	4E-01	1.07 (0.91, 1.25)	Univariable MR	Weighted Median	Female
Adult body size	221	-0.10	0.17	5E-01	0.91 (0.65, 1.27)	Univariable MR	MR-Egger Inverse variance weighted	Female
Childhood body size	69	-0.13	0.08	2E-01	0.88 (0.75, 1.04)	Univariable MR	Inverse variance weighted	Male
Childhood body size	69	-0.20	0.11	1E-01	0.82 (0.66, 1.01)	Univariable MR	Weighted Median	Male
Childhood body size	69	-0.27	0.19	2E-01	0.76 (0.52, 1.11)	Univariable MR	MR-Egger Inverse variance weighted	Male
Adult body size	168	0.00	0.06	1E+00	1.00 (0.89, 1.12)	Univariable MR	Inverse variance weighted	Male
Adult body size	168	-0.14	0.09	2E-01	0.87 (0.73, 1.04)	Univariable MR	Weighted Median	Male
Adult body size	168	-0.25	0.18	2E-01	0.78 (0.55, 1.11)	Univariable MR	MR-Egger Inverse variance weighted	Male
Childhood body size	267	-0.27	0.06	1E-06	0.76 (0.69, 0.85)	Multivariable MR	Inverse variance weighted	All
Adult body size	535	0.23	0.05	2E-06	1.26 (1.14, 1.38)	Multivariable MR	Inverse variance weighted	All
Childhood body size	132	-0.14	0.08	8E-02	0.87 (0.75, 1.01)	Multivariable MR	Inverse variance weighted	Female
Adult body size	202	0.13	0.07	6E-02	1.14 (0.99, 1.31)	Multivariable MR	Inverse variance weighted	Female
Childhood body size	132	-0.31	0.08	1E-04	0.74 (0.63, 0.86)	Multivariable MR	Inverse variance weighted	Male
Adult body size	202	0.28	0.07	1E-04	1.33 (1.15, 1.53)	Multivariable MR	Inverse variance weighted	Male

807 *Number of single-nucleotide polymorphisms (SNPs)
 808

809 **Table 2.** Univariable and multivariable Mendelian randomization analyses for
 810 birthweight, childhood and adult body size onto fracture risk in later life and estimated
 811 bone mineral density
 812
 813

Exposure	Outcome	nSNPs*	Beta	Standard error	p value	Odds ratio (95% confidence interval)	Mendelian randomization (MR)
Birthweight	Fracture risk in later life	174	0.08	0.04	3E-02	1.08 (1.01, 1.16)	Univariable MR
Childhood body size	Fracture risk in later life	313	-0.12	0.04	5E-03	0.89 (0.82, 0.96)	Univariable MR
Adult body size	Fracture risk in later life	580	0.08	0.03	2E-02	1.08 (1.01, 1.16)	Univariable MR
Birthweight	eBMD	174	-0.08	0.03	1E-02	(-0.14, 0.02)	Univariable MR
Childhood body size	eBMD	313	0.26	0.03	3E-16	(0.20, 0.33)	Univariable MR
Adult body size	eBMD	580	0.20	0.02	1E-17	(0.15, 0.25)	Univariable MR
Birthweight	Fracture risk in later life	148	0.10	0.03	3E-03	1.10 (1.03, 1.17)	Multivariable MR
Childhood body size	Fracture risk in later life	203	-0.25	0.06	7E-05	0.78 (0.69, 0.88)	Multivariable MR
Adult body size	Fracture risk in later life	396	0.19	0.05	3E-04	1.21 (1.09, 1.35)	Multivariable MR
Birthweight	eBMD	148	-0.11	0.02	1E-05	(-0.16, -0.06)	Multivariable MR
Childhood body size	eBMD	203	0.21	0.05	2E-05	(0.11, 0.30)	Multivariable MR
Adult body size	eBMD	396	0.11	0.04	1E-02	(0.02, 0.19)	Multivariable MR

814 *Number of single-nucleotide polymorphisms (SNPs)
 815

816 **Table 3.** Two-step Mendelian randomization analyses for childhood and adult body size
 817 onto potential mediators and potential mediators onto fracture risk in later life and
 818 estimated bone mineral density
 819

Exposure	Mediator/ Outcome	nSNPs*	Beta	Standard error	p value	Odds ratio (95% confidence interval)	Mendelian randomization (MR)	Method	Sex
Childhood body size	eBMD	313	0.26	0.03	3E-16	(0.20, 0.33)	Univariable MR	Inverse variance weighted	All
Childhood body size	eBMD	313	0.25	0.03	7E-21	(0.20, 0.30)	Univariable MR	Weighted median	All
Childhood body size	eBMD	313	0.36	0.07	1E-06	(0.21, 0.50)	Univariable MR	MR Egger	All
Childhood body size	eBMD	142	0.18	0.04	7E-06	(0.10, 0.26)	Univariable MR	Inverse variance weighted	Female
Childhood body size	eBMD	142	0.22	0.04	5E-10	(0.15, 0.29)	Univariable MR	Weighted median	Female
Childhood body size	eBMD	142	0.27	0.09	4E-03	(0.09, 0.44)	Univariable MR	MR Egger	Female
Childhood body size	eBMD	69	0.36	0.06	3E-08	(0.23, 0.49)	Univariable MR	Inverse variance weighted	Male
Childhood body size	eBMD	69	0.37	0.05	6E-13	(0.27, 0.47)	Univariable MR	Weighted median	Male
Childhood body size	eBMD	69	0.44	0.15	4E-03	(0.15, 0.73)	Univariable MR	MR Egger	Male
Adult body size	eBMD	580	0.20	0.02	1E-17	(0.15, 0.25)	Univariable MR	Inverse variance weighted	All
Adult body size	eBMD	580	0.22	0.02	1E-29	(0.18, 0.26)	Univariable MR	Weighted median	All
Adult body size	eBMD	580	0.24	0.07	3E-04	(0.11, 0.37)	Univariable MR	MR Egger	All
Adult body size	eBMD	221	0.16	0.04	9E-06	(0.09, 0.24)	Univariable MR	Inverse variance weighted	Female
Adult body size	eBMD	221	0.16	0.03	3E-07	(0.10, 0.23)	Univariable MR	Weighted median	Female
Adult body size	eBMD	221	0.22	0.11	5E-02	(0.00, 0.44)	Univariable MR	MR Egger	Female
Adult body size	eBMD	168	0.34	0.04	4E-14	(0.25, 0.42)	Univariable MR	Inverse variance weighted	Male
Adult body size	eBMD	168	0.37	0.05	7E-16	(0.28, 0.45)	Univariable MR	Weighted median	Male
Adult body size	eBMD	168	0.52	0.13	2E-04	(0.26, 0.78)	Univariable MR	MR Egger	Male
Childhood body size	Calcium	313	-0.10	0.02	6E-07	(-0.15, -0.06)	Univariable MR	Inverse variance weighted	All
Childhood body size	Calcium	313	-0.09	0.02	1E-05	(-0.13, -0.05)	Univariable MR	Weighted median	All
Childhood body size	Calcium	313	-0.11	0.05	2E-02	(-0.20, -0.02)	Univariable MR	MR Egger	All
Childhood body size	Vitamin D	313	-0.07	0.02	5E-05	(-0.10, -0.04)	Univariable MR	Inverse variance weighted	All
Childhood body size	Vitamin D	313	-0.06	0.02	2E-03	(-0.10, -0.02)	Univariable MR	Weighted median	All
Childhood body size	Vitamin D	313	-0.11	0.04	3E-03	(-0.19, -0.04)	Univariable MR	MR Egger	All
Adult body size	Calcium	580	-0.05	0.02	6E-03	(-0.08, -0.01)	Univariable MR	Inverse variance weighted	All
Adult body size	Calcium	580	-0.07	0.02	6E-05	(-0.10, -0.03)	Univariable MR	Weighted median	All
Adult body size	Calcium	580	-0.09	0.05	7E-02	(-0.20, 0.01)	Univariable MR	MR Egger	All
Adult body size	Vitamin D	580	-0.18	0.01	1E-37	(-0.21, -0.15)	Univariable MR	Inverse variance weighted	All
Adult body size	Vitamin D	580	-0.19	0.02	3E-32	(-0.22, -0.16)	Univariable MR	Weighted median	All
Adult body size	Vitamin D	580	-0.18	0.04	2E-05	(-0.26, -0.10)	Univariable MR	MR Egger	All
Childhood body size	eBMD	267	0.20	0.04	3E-07	(0.12, 0.27)	Multivariable MR	Inverse variance weighted	All
Adult body size	eBMD	535	0.09	0.03	8E-03	(0.02, 0.15)	Multivariable MR	Inverse variance weighted	All
Childhood body size	eBMD	132	0.21	0.04	5E-07	(0.13, 0.29)	Multivariable MR	Inverse variance weighted	Female
Adult body size	eBMD	202	0.04	0.04	3E-01	(-0.03, 0.12)	Multivariable MR	Inverse variance weighted	Female
Childhood body size	eBMD	58	0.20	0.07	8E-03	(0.05, 0.35)	Multivariable MR	Inverse variance weighted	Male
Adult body size	eBMD	161	0.14	0.06	3E-02	(0.02, 0.27)	Multivariable MR	Inverse variance weighted	Male
Childhood body size	Calcium	267	-0.11	0.03	1E-04	(-0.17, -0.05)	Multivariable MR	Inverse variance weighted	All
Adult body size	Calcium	535	0.01	0.03	6E-01	(-0.04, 0.06)	Multivariable MR	Inverse variance weighted	All
Childhood body size	Vitamin D	267	0.07	0.02	3E-03	(0.02, 0.11)	Multivariable MR	Inverse variance weighted	All
Adult body size	Vitamin D	535	-0.22	0.02	4E-30	(-0.26, -0.18)	Multivariable MR	Inverse variance weighted	All
eBMD	Fractures	548	-0.48	0.02	5E-150	0.62 (0.60, 0.64)	Univariable MR	Inverse variance weighted	All
eBMD	Fractures	548	-0.48	0.02	3E-91	0.62 (0.59, 0.65)	Univariable MR	Weighted median	All
eBMD	Fractures	548	-0.54	0.04	9E-41	0.58 (0.54, 0.63)	Univariable MR	MR Egger	All
eBMD	Fractures	323	-0.51	0.02	2E-112	0.60 (0.57, 0.63)	Univariable MR	Inverse variance weighted	Female
eBMD	Fractures	323	-0.56	0.03	9E-77	0.57 (0.54, 0.61)	Univariable MR	Weighted median	Female
eBMD	Fractures	323	-0.59	0.05	1E-29	0.55 (0.51, 0.61)	Univariable MR	MR Egger	Female
eBMD	Fractures	206	-0.37	0.03	5E-40	0.69 (0.65, 0.73)	Univariable MR	Inverse variance weighted	Male
eBMD	Fractures	206	-0.47	0.04	1E-38	0.63 (0.58, 0.67)	Univariable MR	Weighted median	Male
eBMD	Fractures	206	-0.47	0.06	2E-13	0.62 (0.55, 0.70)	Univariable MR	MR Egger	Male
Calcium	Fractures	355	-0.01	0.02	8E-01	0.99 (0.95, 1.04)	Univariable MR	Inverse variance weighted	All

Calcium	Fractures	355	0.01	0.03	7E-01	1.01 (0.95, 1.08)	Univariable MR	Weighted median	All
Calcium	Fractures	355	0.01	0.05	8E-01	1.01 (0.92, 1.10)	Univariable MR	MR Egger	All
Vitamin D	Fractures	131	0.02	0.03	5E-01	1.02 (0.96, 1.09)	Univariable MR	Inverse variance weighted	All
Vitamin D	Fractures	131	-0.02	0.05	8E-01	0.98 (0.89, 1.09)	Univariable MR	Weighted median	All
Vitamin D	Fractures	131	0.00	0.05	1E+00	1.00 (0.91, 1.10)	Univariable MR	MR Egger	All
Calcium	eBMD	355	-0.04	0.02	4E-02	(-0.07, 0.00)	Univariable MR	Inverse variance weighted	All
Calcium	eBMD	355	-0.04	0.02	2E-02	(-0.06, -0.01)	Univariable MR	Weighted median	All
Calcium	eBMD	355	-0.02	0.03	5E-01	(-0.09, 0.05)	Univariable MR	MR Egger	All
Vitamin D	eBMD	131	-0.01	0.02	6E-01	(-0.06, 0.03)	Univariable MR	Inverse variance weighted	All
Vitamin D	eBMD	131	-0.04	0.02	1E-02	(-0.07, -0.01)	Univariable MR	Weighted median	All
Vitamin D	eBMD	131	-0.02	0.03	5E-01	(-0.09, 0.05)	Univariable MR	MR Egger	All

820 *Number of single-nucleotide polymorphisms (SNPs)